...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

Is there a medical difference between the 2 Clinical Trials?

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

https://clinicaltrials.gov/ct2/show/NCT04471974

vs the trial that was halted :

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

https://clinicaltrials.gov/ct2/show/NCT04191096

(Bolding added by me)

Koo

 

Share
New Message
Please login to post a reply